INS and MODY: This suggests that FDA patients, rather than carrying mutations grossly affecting insulin synthesis and/or secretion (as in the case of MODY patients) are more likely to carry mutations involved in the fine tuning of insulin secretion or grossly affecting inulin sensitivity.